BEIJING, Feb. 5, 2026 /PRNewswire/ — China unveiled its “No.1 central document” for 2026 on Tuesday, outlining plans to advance agricultural and rural modernization and to promote all-around rural revitalization, according to the Xinhua News Agency.

As the first major policy document on agriculture and rural affairs issued at the start of the 15th Five-Year Plan period (2026-30), analysts said the document is expected to help translate the vast potential of agriculture and rural areas into concrete drivers of economic growth and high-quality development.

This marks the 14th No.1 central document focusing on agriculture and rural work since the 18th National Congress of the Communist Party of China in 2012. As the first policy statement released by central authorities each year, the document is widely seen as a barometer of policy priorities.

According to Xinhua, the document consists of six sections covering efforts to enhance agricultural production capacity and efficiency, implement normalized and targeted assistance, promote steady income growth for farmers, advance livable and business-friendly rural development, enhance institutional innovation, and strengthen the Party’s leadership over agriculture, rural areas and farmers.

The document notes that the 15th Five-Year Plan period is a critical stage for laying the foundation for basically realizing socialist modernization, calling for efforts to shore up weak links in agriculture and rural areas, and secure faster progress in building up China’s strength in agriculture.

Among the key highlights, the document places particular emphasis on boosting comprehensive agricultural production capacity and quality efficiency, and for the first time makes systematic arrangements for implementing normalized and targeted assistance.

Chinese economists said the document sets higher development benchmarks while strengthening baseline safeguards through a system-wide modernization approach, helping lay a solid foundation for accelerating agricultural and rural modernization during the 15th Five-Year Plan period and supporting high-quality growth and domestic demand.

Boosting food security through technology

The document calls for improving the effectiveness of policies that strengthen agriculture, benefit farmers and promote rural prosperity, while firmly safeguarding national food security and upgrading rural industries. It also stresses efforts to build agriculture into a modernized major industry and improve farmers’ livelihoods, providing support for Chinese modernization, according to Xinhua.

By anchoring agricultural development firmly in modernization, the document sets a high bar even by international standards and reflects policymakers’ determination to advance agricultural and rural modernization through systemic reform, said Hu Qimu, deputy secretary-general of the Forum 50 for Digital-Real Economies Integration.

“The goal goes beyond agricultural output, aiming to build a coordinated framework linking population mobility, rural development and industrial growth,” Hu told the Global Times on Tuesday.

Food security remains the top priority and a firm red line, according to the document. It sets a target of keeping grain output at around 1.4 trillion jin (700 million tons), providing a clear benchmark for the first year of the 15th Five-Year Plan period and underscoring China’s resolve to keep its food supply firmly in its own hands.

The document sets out new measures to stabilize grain and edible oil production, including stepping up a new round of the 50-million-ton grain capacity enhancement program and promoting integrated use of farmland, seeds, machinery and farming techniques to raise yields at scale.

Zhao Changbao, director of the Rural Economy Research Center at the Ministry of Agriculture and Rural Affairs, said boosting per-unit yields of major grain and oil crops is key to strengthening food security, improving the match between supply and demand, and supporting farmers’ income growth, CCTV reported on Tuesday.

Wang Gangyi, a professor at Northeast Agricultural University, told the Global Times that technology – including bio-breeding, AI and digital technologies – has become the key variable and the critical breakthrough for raising grain output under resource constraints in China.

These priorities are translated into concrete measures in the document, which calls for accelerating the breeding and promotion of breakthrough crop varieties, expanding applications of drones, the Internet of Things and robotics, and ensuring agricultural technologies reach villages.

Official data show that China’s contribution rate of agricultural science and technology progress exceeds 64 percent, and independently bred crop varieties account for more than 95 percent of planted areas.

Normalized targeted assistance

Another major highlight is the call to implement normalized and targeted assistance, marking the first time the No.1 central document has made systematic arrangements for this policy.

The move reflects the evolving policy needs. Although China achieved decisive success in poverty alleviation in 2020 and consolidated the results through a five-year transition period, risks of falling back into poverty remain, making it necessary to shift support measures from temporary arrangements to a normalized and institutionalized framework, members of the document’s drafting group said, according to a Xinhua report.

The document outlines measures to improve the policy system for normalized assistance, enhance monitoring precision and timeliness, strengthen industrial and employment-based support, and provide differentiated assistance to underdeveloped regions. It also incorporates normalized assistance into the overall rural revitalization strategy, while maintaining policy stability in fiscal input, financial support and resource allocation.

Hu said the policy shift reflects a move toward more focused and efficient support as rural industrial foundations and farmers’ income-generating capacity improve, providing stronger institutional safeguards for consolidating poverty alleviation gains.

In addition to these key measures, the document also stresses promoting steady income growth for farmers through coordinated policies on prices, subsidies and insurance, fostering county-level industries and stabilizing employment for migrant workers.

As the first major sector-specific policy released in the 15th Five-Year Plan period (2026-30), the document aims to systematically turn rural potential into tangible growth momentum, income gains and jobs, Hu added.

More broadly, experts noted that while the document focuses on agriculture and rural affairs, it carries wider economic implications. With China’s urbanization rate at 67.89 percent, boosting rural incomes and development capacity is key to expanding domestic demand and supporting the unified national market.

DUBAI, UAE, Feb. 5, 2026 /PRNewswire/ — AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C (“Ambitions” or “the Company”) (NASDAQ: AHMA), a UAE-based MICE (meetings, incentives, conferences, and exhibitions) and tourism services provider, today announced that its wholly-owned subsidiary, MULTIPLE EVENTS L.L.C (“Multiple Events”), will serve as the event planning services provider for the 2026 Middle East Consumer Electronics Show (“MECES”) in Dubai, marking the third consecutive year of business partnership.

Drawing on its expertise in managing large-scale international events, Multiple Events will lead comprehensive event planning, design, coordination and on-site execution for MECES, one of the region’s technology and innovation showcases. The engagement encompasses daily liaison and coordination with exhibition venue management; procurement and management of ancillary services, including catering solutions, food trucks, and network/technical infrastructure; facilitation of all required approvals, permits, and regulatory clearances for exhibitions, entry access, and event operations; and provision of any additional services necessary to ensure the safe, compliant, and seamless execution of exhibitions, conferences, and related activities.

MECES is the first professional exhibition in the Middle East dedicated to the home appliances and consumer electronics sector, showcasing the latest in consumer technology, innovation trends, and market developments. The previous two editions attracted thousands of professional buyers and visitors from the UAE, Saudi Arabia, Qatar, and other counties across the Middle East, alongside leading global brands and emerging technology companies, reinforcing its position as a premier platform for cross-border collaboration and commercial exchange across a diverse regional market. Ambitions’ role in planning and delivering the event reflects its strategic focus on high-profile partnerships that bridge global audiences and strengthen the UAE’s position as a hub for international conferences and exhibitions.

About AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C

As a UAE-based MICE and tourism services provider, the Company serves a global client base by delivering expert event management and seamless, one-stop travel solutions. Guided by an experienced management team and supported by partnerships across the tourism and hospitality industries in the Middle East, Europe, Africa, and the Americas, the Company executes large-scale events for clients from diverse sectors. Additionally, the Company manages bespoke travel experiences, providing a one-stop guided tour service that streamlines travel across the UAE and its neighboring countries, as well as to other global destinations.

For more information, please visit https://ir.ambitions.ae.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “would,” “may,” “expects,” “anticipates,” “aims,” “future,” “continues,” “could,” “should,” “target,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar expressions. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the United States Securities and Exchange Commission.

For investor and media inquiries, please contact:

AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C
Investor Relations
Email: Ambitions@thepiacentegroup.com

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: Ambitions@thepiacentegroup.com

Jenny Cai
Tel: +86-10-6508-0677
Email: Ambitions@thepiacentegroup.com

BEIJING, Feb. 5, 2026 /PRNewswire/ — Cloopen Group Holding Limited (OTC: RAASY) (“Cloopen” or the “Company”) today announced that its Board of Directors (the “Board”) has approved resolutions regarding changes to the composition of the Board and the Compensation Committee, effective February 5, 2026.

Board Composition and Re-appointments The Company announced that Mr. Qingsheng Zheng and Mr. Ye Yuan have tendered their resignations as directors of the Board for personal reasons. Both Mr. Zheng and Mr. Yuan have confirmed that they have no disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Following these resignations, the Board has approved the re-appointment of both Mr. Qingsheng Zheng and Mr. Ye Yuan as directors of the Company, conditional upon and effective from the date on which the Board receives their duly executed consent to act.

Change in Board Committee Membership The Company further announced changes to the membership of the Compensation Committee of the Board. Mr. Ye Yuan has resigned from his position as a member of the Compensation Committee, effective February 5, 2026.

Concurrently, the Board has appointed Mr. Pengfei Yuan, a current director of the Company, to serve as a member of the Compensation Committee, effective February 5, 2026.

About Cloopen Group Holding Limited

Cloopen Group Holding Limited is a leading multi-capability cloud-based communications solution provider in China offering a full suite of cloud-based communications solutions, covering communications platform as a service (CPaaS), cloud-based contact centers (cloud-based CC), and cloud-based unified communications and collaborations (cloud-based UC&C). Cloopen’s mission is to enhance the daily communication experience and operational productivity for enterprises. Cloopen aspires to drive the transformation of enterprise communications industry by offering innovative marketing and operational tactics and SaaS-based tools.

For more information, please visit https://ir.yuntongxun.com.

Forward-Looking Statements

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Cloopen may also make written or oral forward-looking statements in its reports filed with or furnished to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Cloopen’s beliefs and expectations as well as its financial outlook, are forward-looking statements. These forward-looking statements are based on Cloopen’s current expectations and involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Cloopen’s filings with the SEC. All information provided in this press release is current as of the date of the press release, and Cloopen does not undertake any obligation to update such information, except as required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement, and you are cautioned not to place undue reliance on these forward-looking statements.

For investor and media inquiries, please contact:

Cloopen Group Holding Limited
Investor Relations
Email: ir@yuntongxun.com 

TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly^® in the EU) in Japan.

Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies.^[1] In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world’s first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.

In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.

In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs.^{[2],[3],[4],[5]}

Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.

Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.

“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”

“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”

* Converted at an exchange rate of USD 1 = JPY 155

Notes to Editors

1.     About Serplulimab
Serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly^® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world’s first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru).

Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.

2.     About Eisai Co., Ltd.
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.

3.     About Shanghai Henlius Biotech, Inc. 
Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.

Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly^® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.